Molecular Devices has partnered with the Discovery Technologies team at the Roche announced a biotech partnership to develop a high-throughput detection system for drug discovery screens employing Roche's proprietary Ruthenium-based nanosecond time resolved fluorescence (Nano-TRF) assays.
The pRED screening teams in Basel and Shanghai are now installing the custom-developed Nano-TRF cartridge in their existing Molecular Devices SpectraMax Paradigm multimode microplate readers and will receive on-demand delivery of new cartridges and continuing global technical support.
Molecular Devices' SpectraMax Paradigm Multi-Mode Detection Platform employs a cartridge-based system that expands the capability of the plate reader beyond traditional assays to include applications such as western blotting and imaging cytometry.
Users can choose from more than 20 existing cartridges or engage Molecular Devices Custom Technologies to create a cartridge that fits their needs.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Roche
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity